SCHEMBL13010331

SCHEMBL13010331

COc1ccc(C[C@@H](CN)N(C)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.46
SLC6A4 P31645 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALOX5 P09917 1/20 0.38
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
MMP1 P03956 1/20 0.37
ACACB O00763 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22035315 0.86 ADORA1 (0.43) SLC6A4CYP1A2CYP2D6CYP2C19ALDH1A1
SCHEMBL6316448 0.85 ATM (0.42) OPRM1OPRD1OPRK1L3MBTL1
SCHEMBL3777215 0.82 LDHA (0.46) LDHASLC6A4L3MBTL1CYP1A2CYP2D6
SCHEMBL6942693 0.81 LDHA (0.54) LDHAL3MBTL1PPARGPPARATDP1
SCHEMBL3776724 0.81 LDHA (0.54) LDHAL3MBTL1PPARGPPARATDP1
SCHEMBL3638571 0.80 LDHA (0.46) LDHAL3MBTL1HTTPPARGPPARA
SCHEMBL3777213 0.77 LDHA (0.46) LDHASLC6A4L3MBTL1CYP1A2CYP2D6
SCHEMBL3700726 0.76 LDHA (0.50) LDHASLC6A4L3MBTL1CYP1A2CYP2D6
SCHEMBL2014842 0.75 ATM (0.41) OPRM1OPRD1OPRK1L3MBTL1ALDH1A1
SCHEMBL3807212 0.75 ATM (0.41) OPRM1OPRD1OPRK1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317697-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-12-16 US disclosed
WO-2009096996-A1 RENIN INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317697-A1 Renin Inhibitors REN, ACE, SERPINB1 LDHA 843/4885SLC6A4 2399/4885OPRM1 3016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.